Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity of $454.27M in Q2 FY2026
Q2 FY2026 total equity was $454.27M.
Context
- Total equity amounted to 97.1% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- (176.64M) USD
- Year-over-year change
- —
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (176.64M) | — |
Total Equity vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 total equity of $454.27M is the 3rd highest of the 5 companies compared; the peer median is $329.8M.
- Total equity amounts to 97.1% of total assets for COAG, versus a peer median of 89.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
IRONDisc Medicine, Inc. | Sep 2026 | $604.25M | +5.4% | +61.2% | 86.4% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $510.26M | +4032.0% | +57.3% | 95.3% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $454.27M | — | — | 97.1% |
| Mar 2026 | $149.34M | +343.3% | -25.2% | 19.2% | |
| Mar 2026 | $50.28M | -7.0% | -30.0% | 92.3% | |
| Peer median (excluding COAG) | $329.8M | +174.4% | +16.0% | 89.3% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.